Thank you for laying out those share numbers, it's tedious work , I know. A few things to consider though; in respect of HIV , the major expenses are in the past,launch will be paid by Vyera.
Second, a billion shares would be nearly a 50% increase ,and the majority of shares issued are a result of capital raising at much lower prices.ie; even dilutive funding would,at current prices ,mean relatively more money per share issued than in the past.
Third, although there are many trials to fund,the company will likely have more non dilutive funding options from herein.
Fourth, if leronlimab is proved as the best short and medium term treatment for corona virus,as seems currently likely to occur,then that should be revenue positive.